Effects of Intermittent Pneumatic Compression on Delayed Onset Muscle Soreness (DOMS) in Long Distance Runners by Draper, Shane N.
Cleveland State University
EngagedScholarship@CSU
ETD Archive
2014
Effects of Intermittent Pneumatic Compression on
Delayed Onset Muscle Soreness (DOMS) in Long
Distance Runners
Shane N. Draper
Cleveland State University
Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Education Commons
How does access to this work benefit you? Let us know!
This Thesis is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for inclusion in ETD Archive by an
authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Recommended Citation
Draper, Shane N., "Effects of Intermittent Pneumatic Compression on Delayed Onset Muscle Soreness (DOMS) in Long Distance
Runners" (2014). ETD Archive. 716.
https://engagedscholarship.csuohio.edu/etdarchive/716
EFFECTS OF INTERMITTENT PNEUMATIC COMPRESSION ON DELAYED 
ONSET MUSCLE SORENESS (DOMS) IN LONG DISTANCE RUNNERS 
SHANE N. DRAPER 
 
 
 
Bachelor of Science in Recreation Management and Youth Leadership 
Brigham Young University 
December 2011 
 
 
 
Submitted in partial fulfillment of requirements for the degree  
MASTER OF EDUCATION 
at the 
CLEVELAND STATE UNIVERISTY 
July 2014 
 
 
 
 
  
  
 
 
 
© COPYRIGHT BY SHANE NICHOLAS DRAPER 2014 
  
We hereby approve this thesis for  
Shane N. Draper 
Candidate for the Master of Education in Exercise Science degree  
for the College of Education and Human Services,  
Department of Health and Human Performance 
and the CLEVELAND STATE UNIVERSITY 
College of Graduate Studies 
 
________________________________________________________________________ 
Thesis Chairperson, Dr. Kenneth Sparks 
 
_________________________________________________ 
Department & Date 
 
________________________________________________________________________ 
Thesis Committee Member, Dr. Kathleen Little 
 
________________________________________________ 
Department & Date 
 
________________________________________________________________________ 
Thesis Committee Member, Dr. Emily Kullman 
 
________________________________________________ 
Department & Date 
 
 
 ________________________________________________________________________ 
Thesis Committee Member, Dr. Joan Thoman 
 
__________________________________________________ 
Department & Date 
 
_______________________________________________________________________ 
Associate Dean of Student Services, Dr. Jane Zaharias 
 
__________________________________________________ 
Department & Date 
 
The Effects of Intermittent Pneumatic Compression on Delayed Onset Muscle Soreness 
(DOMS) in Long Distance Runners 
(Title) 
 
Student’s Date of Defense: (07/28/2014) 
  
Acknowledgments 
I would like to thank the following individuals for their assistance and encouragement 
with my thesis: 
Robyn, Erik, and DeAnn Draper, family and friends 
Gilad Jacobs at NormaTec 
Louis Keppler M.D. at Saint Vincent Charity Hospital 
Kathy Ciszczon at Saint Vincent Charity Hospital 
Kenneth Sparks, Ph.D. 
Kathleen Little, Ph.D. 
Emily Kullman, Ph.D. 
Joan Thoman, Ph.D., RN, CNS, CDE 
 
 
  
vi 
 
EFFECTS OF INTERMITTENT PNEUMATIC COMPRESSION ON DELAYED 
ONSET MUSCLE SORENESS (DOMS) IN LONG DISTANCE RUNNERS 
SHANE N. DRAPER 
ABSTRACT 
     Purpose: The purpose was to measure the effects of intermittent pneumatic 
compression (NormaTec, NT) on muscle inflammation after long distance running. 
Methods: Ten long distance runners, five males and five females, ages 18-55 years 
performed two, 20 mile runs at 70% VO2 max. The runs were followed by either no 
treatment (control) or NT treatment for five consecutive days. For the NT run, subjects 
were treated for one hour immediately following the run and daily for five days after. For 
the control run, subjects did not receive any treatment. Serum C – reactive protein (CRP), 
a marker of muscle inflammation, was measured pre and post run and daily thereafter for 
five days for both trials. Repeated measures ANOVA and two-way ANOVA were used to 
assess treatment differences. Results: The results indicated no significant difference (P > 
0.05) between the control and treatment runs in CRP levels. There was also no gender 
differences or order effect of runs. Subjective pain ratings indicated no significant 
difference in pain between the control and treatment runs except when comparing the 
first run compared to the second run (regardless of whether the first run was a treatment 
or control run); there was a significant difference in which the subjects experienced less 
pain on the second run. There was no significant difference in mean weight loss, fluid 
intake, sweat rate, heart rate, percentage of maximum heart rate, or percentage of 
maximum VO2 max. There was, however, a significant difference (P = 0.038) in running 
vii 
 
time when comparing the control run (196.2 minutes) against the treatment run (204.8 
minutes). Conclusions: Although the test subjects recovered one day earlier when using 
the NT device (Day 4) compared to the control (Day 5), this difference was not 
significant. 
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CHAPTER I 
INTRODUCTION 
Background 
     Delayed onset of muscle soreness (DOMS) is an effect of performing an exercise that 
places a great deal of strain on the skeletal muscles, especially eccentric exercise (1).  
Armstrong (2) has proposed a DOMS Model which includes a series of events occurring 
from DOMS to recovery.  It is proposed that DOMS causes damage to the sarcolemma, 
the muscle cell membrane.  This damage results in the release of biochemical markers of 
muscle damage (e.g. lactate dehydrogenase (LDH), creatine kinase (CK), and myoglobin 
(Mb). The inflammation process begins as a precursor to full recovery of damaged 
muscle fibers. Inflammation, indicated by the blood marker C-reactive protein (CRP), 
denotes the onset of the healing process (2).
 
     
In 2002, the NormaTec Pneumatic Compression Device (NTPCD) was introduced to 
the world of external compression. It was backed as an FDA cleared medical device 
which yielded highly effective results for patients who had been diagnosed with 
peripheral vascular diseases (PVD) (3). The NTPCD differentiates from other external 
compression devices because of its patented peristaltic pulse pneumatic waveform. This 
peristaltic pulse was a major advancement that went beyond the existing and already 
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established inflation and deflation strategies (non-sequential, sequential, and sequential 
gradient) used in the 1960s to 1980s (3).
 
     In 2007, NT extended its technology from clinical medicine to sports medicine as a 
recovery tool for athletes. The sequential pulse technology compression (peristaltic pulse 
pneumatic waveform, in the sports medicine jargon) is based on normal physiology and 
combines three distinctive massage techniques to speed the body’s natural recovery 
process (3). The first technique is pulsing. Sequential pulse technology uses pulsing, or 
dynamic compression, to more effectively mimic the muscle pump of the legs and arms. 
This dynamic compression greatly enhances the movement of fluid and metabolites out 
of the muscles after intense workouts. The second technique is gradients. Sequential 
pulse technology uses gradient hold pressures to prevent body fluids from being forced 
down to the feet by the pulsing actions described previously. The gradient hold allows 
maximum pressure to be delivered throughout the entire limb and the effectiveness of the 
pulsing action is not curtailed at the top of the limb. The third technique is distal release. 
Extended static pressure can not only be detrimental to the body’s natural circulatory 
flow, but to the limb where the pressure is applied as well. The sequential pulse 
technology, however, releases the held pressures placed on the limb once they are not 
needed to prevent backflow of blood. In releasing the held pressure in each zone as 
quickly as possible, each portion of the limb gains maximal recovery time without a 
significant pause between compression cycles (4, Appendix A). 
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Statement of the Problem 
     Research is needed in order to determine if the NT recovery unit is effective in the 
reduction of muscle inflammation after long distance running. If the NT recovery unit can 
speed recovery as well as reduce the effects of DOMS on athletes, this may allow for 
athletes to enhance their training by helping them recover quicker and by allowing them 
to train harder. 
Purpose of the Study 
     The purpose of this study was to measure the effects of intermittent pneumatic 
compression (NT) on the muscle inflammation marker C-reactive protein (CRP) and 
DOMS in trained athletes after long distance running. 
Hypothesis 
     NT treatment will reduce inflammation, as indicated by the blood marker C-reactive 
protein (CRP), and reduce delayed onset muscle soreness (DOMS).
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CHAPTER II 
 
LITERATURE REVIEW 
     The literature review discusses DOMS and exercise-induced muscle damage, potential 
effects of massage and other recovery treatments (relatively older forms of treatment), 
and intermittent pneumatic compression (relatively newer form of treatment) on DOMS 
and exercise-induced muscle damage.  
DOMS and Exercise Induced Muscle Damage 
     Milias et al. (5) sought to determine if a relationship existed between platelet activator 
factor (PAF) and eccentric exercise induced muscle damage. The subjects consisted of 13 
healthy, active males who had not participated in any kind of resistance training for a 
minimum of six months before participating in the study.  
     Subjects performed six sets of six repetitions (maximum eccentric actions of the 
elbow flexors) with their non-dominant arm using a motorized muscle dynamometer with 
a one minute rest period between sets. Venous blood samples were collected from the 
dominant arm immediately prior to, and following the non-dominant arm exercise. 
Additional blood samples were taken 2, 24, 48, 72, and 96 hours following the exercise. 
PAF, C-reactive protein(CRP), creatine kinase (CK), fibrinogen, lactate dehydrogenase 
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(LDH), complement C3, and whole blood level leukocytes (including their subsets) were 
determined. 
     The results indicated CK, LDH, leukocytes, and PAF were the only biochemical 
markers which elevated and showed statistically significant differences following 
exercise. The authors concluded a possible role of PAF in the mechanism of exercise 
induced muscle injury and suggested future research investigate the exact features of PAF 
in its role as a mechanism of exercise induced muscle injury, and whether it could be 
utilized as a new marker of muscle damage (5). 
     Nosaka et al. (6) investigated DOMS and enzymes indicating muscle damage 
following eccentric exercise. They enrolled 110 healthy males, mean age 23 years, who 
had not been involved in a resistance exercise training program. Subjects were placed in 
one of two groups based on the number of eccentric exercises they were able to perform. 
The first group (N=50) performed 12 eccentric exercise actions. The second group 
(N=60) performed 24 eccentric exercise actions. 
     Muscle soreness was measured with a visual analog scale indicating “no pain” to 
“unbearable pain” based on three assessments: palpating over the elbow flexors, and 
flexing and extending the elbow joint in a full range of motion. Soreness developed on 
day one following exercise and peaked two to three days after exercise for both groups. 
Time course changes in soreness were similar in palpitation, flexion, and extension. 
However, peak soreness values were significantly smaller for flexion compared to 
palpitation or extension. There were no significant differences between the first group 
and second group for palpitation and flexion soreness, but the second group had 
significantly higher extension soreness values three and four days after exercise 
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compared to the first group. Peak soreness values were similar for the first and second 
group for palpitation and flexion soreness. However, the second group showed 
significantly higher peak extension soreness values compared to the first group. A 
Palpitation soreness did not correlate significantly with any indicators, however, 
extension and flexion soreness revealed a weak (r < 0.32) but significant correlation with 
the other indicators. 
     Maximal isometric force, relaxed and flexed elbow joint angle (RANG and FANG), 
upper arm circumference, and CK were measured before, immediately after, and every 
day after for four consecutive days following the exercise. The results indicated no 
significant difference in the pre-exercise maximal isometric force between the first group 
(12 eccentric exercise actions) and second group (24 eccentric exercise actions). Maximal 
isometric force dropped about 58.1% for the first group and about 47.1% for the second 
group immediately after exercise. The force deficit was significantly larger for the second 
group compared to the first group. Four days after exercise, maximal isometric force had 
recovered to about 73.1% of the pre-exercise value for the first group which was 
significantly larger than the second group which was about 52.5% of the pre-exercise 
value at the same time point. 
     The results for the elbow joint angles for RANG showed a significantly larger mean 
decrease immediately following exercise in the second group compared to the first group. 
Four days post-exercise, RANG was found to still be significantly smaller than the pre-
exercise level for both the first and second groups. However, the amount of decrease 
from baseline was significantly larger for the second group compared to the first group. 
The mean increase in FANG following the second group was significantly larger 
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compared to the mean increase in the first group. Four days post-exercise, FANG was 
found to be still significantly larger than pre-exercise levels for both the first and second 
groups. However, the amount of increase from baseline was significantly larger in the 
second group compared to the first group. 
     Upper arm circumference significantly increased immediately following exercise for 
both the first and second groups. The upper arm circumference continued to increase and 
peaked three to four days post-exercise in both groups but the greatest value in the second 
group was significantly (P<0.01)  larger compared to the first group. 
     Plasma CK activity significantly increased and peaked three to four days post-exercise 
in both groups. However, CK in the second group was significantly higher compared to 
the first group. 
     It appeared the degree of DOMS associated with eccentric exercise was not affected 
by the severity of muscle damage. Likewise, levels of muscle soreness either have little 
or no correlation with other commonly used muscle damage indicators. Thus, 
preventative or treatment measures for DOMS are not the same as preventative or 
treatment measures for muscle degeneration and regeneration. The authors further 
suggested that finding preventative or treatment measures which reduce strength loss or 
plasma CK responses are not necessarily effective in treating DOMS and that in the 
absence of DOMS, muscle damage and the loss of muscle function will persist. So using 
DOMS to judge the degree of muscle damage is not recommended. However, when used 
jointly with other indicators of muscle damage, DOMS can provide further evidence of 
changes within the muscle (6). 
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     Lee, Clarkson (7) investigated 60 untrained healthy males and females ages 18 to 30 
years who had not previously been involved in a weight training program for six months 
for the determination of total resting glutathione levels. The first 30 test subjects had 
three baseline blood draws measured for total glutathione, CK, and myoglobin (Mb). 
Maximal voluntary isometric contraction (MVC) and relaxed arm angle (RANG) were 
also measured. From the initial 60 test subjects, only 17 subjects were included in the 
study’s inclusion criteria of total glutathione (<2.5 or ˃3.8 μmolL-1). The subjects who 
were included in the <2.5 range were put into a low glutathione group (LG, N=8) while 
the subjects in the ˃3.8 range (HG, N= 9) were put into a high glutathione group. 
     The exercise protocol consisted of the subjects performing one set of 50 maximal 
eccentric contractions, three second duration with 12 second rest in between, on a 
modified preacher curl machine. Using a strain gauge attached to the modified preacher 
curl machine, MVC was assessed with three trials. Using a goniometer to measure elbow 
joint angles, RANG was measured with the subject’s arm hanging at his or her side 
passively with the wrist in a neutral position. The arm was marked at the wrist, elbow, 
and shoulder with a skin marker to ensure day to day measurement reproducibility. 
RANG was determined by taking the mean of the three trials. 
     Baseline measures determined no difference in resting plasma glutathione and CK 
levels over the two baseline days. The intraclass R-value over the two days for CK was 
0.80 for the 17 subjects. A significant group, time, and group by time interaction was 
found for MVC.The RANG results revealed no significant group effect however, there 
was a significant main effect across time and in the group by time interaction. 
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     There was no significant group effect; but there was a significant time effect and 
group by time interaction in CK response. There was a significant group, time, and group 
by time interaction in Mb levels. There was a significant group, time and group by time 
interaction for Glutathione. There was also no significant relationship between 
Glutathione and CK in LG or HG. 
     The authors concluded that subjects with low plasma Glutathione levels had a smaller 
plasma CK and Mb response and recovered faster from eccentric exercise than subjects 
with high plasma Glutathione levels. It was suggested that subjects with low plasma 
Glutathione had a lowered inflammatory response (7).   
     Chleboun et al. (8) enrolled 11 females, ages 19-22 years, who had not been involved 
in a resistance exercise program which included the elbow flexors for 6 months before 
the study. Isometric MVC, were determined using the elbow flexors from three separate 
repetitions on three different days and the subject rested two minutes between each 
contraction. Muscle soreness, isometric strength, stiffness and swelling measurements 
were taken three times before exercise, post exercise and daily for five days and every 
other day during the 2
nd
 week following the exercise bout. The authors used a five point 
scale (0 = no pain; 1 = pain on palpation only; 2 = mild pain with full flexion or extension 
of the elbow; 3 = significant pain with full flexion or extension of the elbow; 4 = constant 
pain) to measure muscle soreness. 
     The authors measured stiffness by using an apparatus which moved by a stepper motor 
in four degree steps. The motor moved from a resting position of 90 degrees to full elbow 
extension and it was programmed to record angle as well as torque 12 seconds after each 
of the 4 degree steps. This allowed for 80-90% of stress relaxation. 
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     A second measure of stiffness was measured by using relaxed arm angle. The amount 
of swelling in the upper arm was measured by using arm circumference and muscle 
compartmental volume by cross-sectional ultrasound imaging. The average peak soreness 
resulted in a score of 2.9 on day two. MVC decreased immediately after exercise and 
reached its lowest point on day one post exercise. Strength remained significantly 
decreased 11 days post exercise. The volume of the flexor muscles exhibited a significant 
increase over pre-exercise volumes. Stiffness increased immediately after exercise and 
remained elevated for the next five subsequent days.  
     It was determined that delayed onset of swelling did not account for the immediate 
rise in muscle stiffness. It was also determined that the increased stiffness was related to a 
change in calcium homeostasis from muscle injury. This suggests stiffness coincides with 
the flexor muscles returning to normal volume, which further indicates that the return to 
normal values from stiffness may be a result of muscle edema (8).   
     Nosaka, Clarkson (9) enrolled 14 males, 20-24 years of age, who had never been 
involved in a weight training program. Six of the 14 subjects were chosen at random to 
be scanned using an MRI. The subjects performed 24 maximal eccentric actions utilizing 
the elbow flexors of their non-dominant arm on a modified arm curl machine. The 
subjects were evaluated for maximal isometric force (MIF), range of motion (ROM), 
circumference (CIR), soreness (SOR), ultrasound images (USG), MRI, CK, aspartate 
aminotransferase (AST), lactate dehydrogenase (LDH), interleukin - 1α (IL-1α), 
interleukin – 1 β (IL-1β), interleukin – 2 (IL-2), interleukin – 6 (IL-6), tumor necrosis 
factor – α (TNF-α), CRP, cortisol and zinc. Measurements were taken immediately 
11 
 
before and after exercise and for five days post- exercise, except the MRI images were 
taken on day 1, 3, 6 pre-exercise and day 10, 23, 31, and 58 post-exercise. 
     MIF was measured on an arm curl machine using a transducer which was connected to 
a digital indicator. The MIF was measured at an elbow joint angle of 90 degrees. Using a 
goniometer, the elbow joint angle ROM was evaluated using flexed (FANG) and relaxed 
(RANG) at the elbow joint. After obtaining FANG and RANG measurements, ROM was 
calculated by subtracting FANG from RANG. Muscle soreness was assessed by using an 
analog scale, based on the subject’s perception, of no pain to very painful. CIR was 
assessed using the upper arm at four different sites (4, 6, 8, 10 cm) above the elbow joint 
with the subject’s arm hanging down by their side.  
     All subjects were assessed using USG (7.5 MHz linear probe) on the same four sites 
used in the CIR measurements to obtain transverse scans of the brachialis and biceps 
brachii. MRIs were taken from the upper arm using the elbow joint as a landmark for 
consistent scanning. Three circular areas of interest, which indicated an increase in signal 
intensity, were set in the transverse section of the biceps brachii or brachialis. The mean 
value from the three ROI was used as a reference during measurement, and was placed in 
the center of the triceps brachii.   
     There was a significant drop in MIF (approximately 55%) in pre-exercise levels 
immediately post exercise. Five days post exercise, MIF was still 70% below pre-exercise 
levels. There was also a significant decrease in ROM immediately following exercise 
with no indication of recovery three days after exercise with a gradual recovery 
following. There was no significant difference in SOR levels between palpation and 
extension of the elbow joint. There were also no significant differences in all four upper 
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arm circumference measurements. In eight of 14 subjects, USG showed an increase in 
echo intensity in the brachialis three to five days post exercise. Increased echo intensity 
was shown by six subjects in both the brachialis and biceps brachii. USG also revealed an 
increase (0.6 cm – 2.2 cm) in muscle thickness with a maximum increase three to four 
days post exercise which remained unchanged for five days after exercise.   
     The elbow flexor muscles showed enlargement in the cross sectional area with 
profound increases in signal intensity at three days post exercise. CK, AST, and LDH 
revealed no significant increase as the changes over time among all the enzymes were 
similar. No significant changes were observed in CRP, cortisol and zinc following 
exercise. The authors concluded that in spite of similar responses in exercise induced 
muscle damage and inflammatory responses accompanying infection or tissue injury, 
there are identifiable differences overall from the classical observance of typical tissue 
damage/repair processes (9). 
     Hosoi et al. (10) enlisted 15 male recreational runners, 41-46 years old, in good health 
with predominantly daily sedentary employment to run a marathon. Following the 
marathon, participants adhered to their normal daily routine; however, due to muscle 
soreness, participants did little running in the first week. The subjects were unable to 
resume their normal training activity for at least two weeks after the marathon.   
     Two weeks before subjects participated in the marathon, each was required to perform 
a maximal exercise test and body impedance was used to determine body fat percentage. 
Venous blood samples were obtained to establish baseline levels on the morning of the 
marathon. The first post race blood sample was drawn within five minutes of each 
subject’s finish and subsequent samples were taken on days 1, 2, 3, 7, and 14 after the 
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marathon. Measures included: total cholesterol (TC), triglycerides (TG), HDL-C, LDL-C, 
free fatty acids (FFA), lactate dehydrogenase (LDH) and hematocrit (Hct).   
     Hematocrit increased significantly from baseline (43.1%) to post race (44.0%). In 
days one, two, and three, hematocrit levels were within 0.3% of baseline. Plasma TG 
levels significantly elevated immediately following the marathon (7%); but, after day one 
and two of recovery, levels fell significantly (28%) below baseline. After one week, TG 
levels returned to baseline. LDL-C levels were not significantly affected by the marathon, 
but gradually fell significantly below baseline levels for three days, returning to baseline 
after one week. HDL-C levels increased 14% the first day following the marathon and 
remained significantly elevated for three days, gradually decreasing to baseline. TC 
increased slightly following the marathon and then significantly fell below baseline after 
two days, returning back to baseline within one week. TC/HDL-C ratio reduced 9 % 
immediately following the marathon and the ratio declined 16% below baseline for three 
days, reaching baseline levels after two weeks. 
     Average CK levels post race tripled from baseline with a continual increase reaching a 
15-fold peak after the first day, falling to baseline levels after one week. LDH levels 
doubled from baseline post race and declined linearly in a two week period towards 
baseline. Post race CK and LDH levels were significantly correlated over time (average 
r=+.71). FFA levels rose by a factor of 10 immediately post race with a rapid decline 
after the first day. With the decreasing values, FFA remained elevated, when compared to 
baseline, for two days. 
     It was determined, through this study, that prolonged strenuous exercise in 
recreational runners produces beneficial changes in lipid blood profiles. However, these 
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changes were only significant for three days. Further, evidence of exercise-induced 
muscle damage occurring during the marathon returned to baseline levels within two 
weeks (10). 
     Schwane et al. (11) enrolled seven healthy males ages 19-21 years who were active in 
aerobic activities but none were highly trained. The subjects performed three treadmill 
exercises in a specific order: VO2 max test, level run, and downhill run. Six subjects 
performed the three outlined consecutive tests separated by six to seven days. The 
seventh subject had a 23 day separation between the first two sets and a 14 day separation 
between the second and third tests. 
     Following the VO2 max, all subjects had a short period of recovery. The subjects ran 
on the treadmill at 0% incline during which their VO2 was measured. The speed attained 
from the recovery run was used on the level and downhill tests. The level test was run at 
0% incline and the downhill test was run at -10%. Subjects ran intermittently for 45 
minutes with two minute rest periods interspersed between five minute runs. During the 
last minute, within each 5 minute bout in the level and downhill tests, VO2 was measured. 
The oxygen requirement for each subject within the exercise was calculated using the 
average of the last minute within each running bout. 
     Blood was drawn from the antecubital vein immediately prior to exercise and five 
minutes 24 hours, 48 hours and 72 hours after the level and downhill runs to determine 
creatine, phosphokinase (CPK) and lactate dehydrogenase (LDH). Additionally, total and 
differential hematocrit (Hct) and white blood cell (WBC) counts were obtained. Muscle 
soreness was evaluated based on a four point scale (0 = complete absence of soreness; 1 
= light pain felt only on palpation; 2 = moderate pain with some stiffness and/or 
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weakness during movement; 3 = severe pain that limits range of motion). The ratings 
were based specifically on the anterior and posterior leg muscle groups (gluteal, 
hamstring, quadriceps). 
     During the level run, VO2 and heart rate were significantly (P < 0.001) higher 
compared to the downhill run; however, there was no difference in stride frequency 
between the two tests. Also, during the level run, muscle soreness was only reported in 
isolated muscle groups. However, it was found through the duration of post exercise, that 
there was no significant increase in muscle soreness found in any muscle group of the 
anterior and posterior part of the leg.    
     Muscle soreness after downhill running was experienced in several different muscle 
groups.  Post exercise muscle soreness ratings had a significant increase compared to pre-
exercise for the anterior and posterior part of the leg. Plasma CPK was not significant 
following the level run; but during the downhill run, 24 hours post exercise CPK values 
were significantly elevated compared to pre-exercise values. At 48 hours post exercise, 
CPK values were not significantly different from 24 hours post exercise, nor from pre-
exercise values. The association (r = 0.53) between plasma CPK and muscle soreness 
over time was significant.   
     There was no significant change from pre to post exercise at any point during the 
study between the level and downhill run, nor was there a correlation (p= - 0.05) between 
muscle soreness and LDH values. Additionally, there were no changes observed in pre-
exercise LDH values in either level or downhill running compared to post exercise LDH 
values.   
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     There was only one significant change in WBC from pre-exercise to post exercise 
immediately following the level run and only one significant change in WBC count 
during the downhill run in which there was a decrease in monocytes 48 hours post 
exercise. The largest change in Hct occurred in one subject 24 hours post exercise during 
the downhill run, -18% pre-exercise value. Changes in Hct levels were observed to be 
fairly stable in the other six subjects. 
     It was determined that delayed onset muscle soreness (DOMS) caused by downhill 
running did not increase WBC indicative of inflammation. It was further determined 
structural changes occurring in muscle tissue as a result of eccentric muscle contractions 
produce plasma enzyme activities and DOMS (11). 
     Millar et al. (12) recruited 21 subjects who were divided into a control group and an 
exercise intervention group, matched by age and gender, to determine the effects of 
aerobic exercise on aspartate aminotransferase (AST), pain, strength, alanine 
aminotransferase (LT), creatine kinase (CK), and range of motion (ROM). The test 
subjects all performed eccentric hamstring contractions using a Biodex isokinetic 
dynamometer consisting of five sets of 10 repetitions. Active knee extension, pain 
ratings, AST, isometric hamstring strength, ROM, AST, and CK were all assessed before 
exercise as well as 24, 48, and 72 hours following exercise. Those in the exercise group 
walked on a motorized treadmill at 50% of their maximum heart rate for 20 minutes at 3, 
24, and 48 hours following exercise. 
     No significant differences were found between the control and exercise intervention 
groups. A trend analysis was run and significant differences were found in the response 
to CK, ROM, and strength. The exercise intervention group continually lost ROM until 
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day three with less ROM compared to the control group. The exercise intervention group 
also experienced a more rapid rise in CK compared to the control group. The authors 
concluded that aerobic exercise used as an intervention did not alleviate the symptoms of 
DOMS and based on the trend analysis, it may even slow down the normal healing 
process (12).             
Effects of Massage on DOMS 
     Zainnuddin et al. (13) tested the hypothesis that if massage was applied after eccentric 
exercise, DOMS would be effectively alleviated without affecting muscle function. They 
enrolled 10 healthy subjects, five women and five men, ages 22-24 years, who had no 
history of upper arm injury nor did they have any experience in resistance training. An 
arm to arm comparison model was used in which one arm served as the control and the 
other served as the treatment condition. Dependent variables measured on the exercised 
arm were maximal isometric and isokinetic voluntary strength, range of motion, upper 
arm circumference, plasma CK, and muscle soreness (VAS, 0 indicating no pain and 100 
indicating extremely painful).  
     The subjects performed 10 sets of six maximal isokinetic eccentric actions involving 
the elbow with each arm with a two week separation between tests. A standard sports 
massage was administered by a professional massage therapist who had been working 
with the Australian football club for several years. One arm was massaged for 10 minutes 
three hours after the eccentric exercise was performed, while the other arm received no 
treatment. Massage techniques used were deeply applied clearing techniques with palmar 
(petrissage) and finger (effleurage) pressure and strokes to the muscle.  
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     The results indicated no significant difference between baseline maximal isometric 
and isokinetic strength between the massage and control arms. Similarly, no significant 
difference existed between peak torque and total work during eccentric exercise. No 
significant differences were observed between maximal isometric torque at an elbow 
angle of 90 degrees and 30 degrees between the massage and control arms. The isometric 
torque values decreased about 60% from the pre-exercise values immediately post 
exercise and remained at these decreased values for two days; torque returned to the pre-
exercise level by 10 days post-exercise. There was no significant difference between the 
massage and control arms for changes in isometric torque over time. 
     The changes in maximal voluntary isokinetic torque were similar to those found in the 
isometric torque throughout the post-exercise period. No significant difference was 
evident between the massage and control arms for any of the velocities tested. 
Additionally, the isokinetic torque values returned to pre-exercise levels by day 10 for 
both conditions. No significant differences were evident in the pre-exercise ROM values 
between the massage and control arms. Immediately post-exercise, ROM decreased 
significantly by about 30% from the baseline and did not recover over the next four days. 
     The upper arm circumference significantly increased during the post-exercise period 
in both conditions, however, the massaged arm showed a significantly smaller increase as 
compared to the control arm. While plasma CK activity significantly increased in both 
conditions post-exercise, there were significantly smaller CK increases in the massaged 
arm as compared to the control arm. Additionally, the massage condition peak value was 
36% lower compared to the control condition. 
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     Peak soreness occurred one to three days post-exercise, whereas peak soreness 
occurred four days post-exercise for the elbow joint extension and all reports of soreness 
were resolved seven days post-exercise. Significant differences existed between the 
massage and control conditions in regard to peak soreness with palpitation and elbow 
joint extension. Massage resulted in a 20% to 40% decrease in muscle soreness compared 
to the control. The authors concluded that massage was effective in reducing the 
magnitude of DOMS, swelling, and plasma creatine kinase. However, massage seemingly 
had no positive effects on muscle strength or ROM (13). 
     Moraska (14) enrolled 317 finishers in a 10 km running race. A questionnaire 
recorded the following information: race finish time, demographic information and 
perceived exertion during the run. The participants rated their muscle soreness on VAS 
with 0 being absence of muscle soreness and 10 indicated extreme muscle soreness.   
     Immediately following the race, subjects were randomly assigned a student massage 
therapist and were blinded to their educational training of their massage therapist. 
Massage students with 450, 700 or 950 hours in didactic massage therapy training 
administered massage in all sessions. Massage was administered to test subjects after the 
10 km race for 12 to 15 minutes, within 15 to 60 minutes after completing the race. 
Student therapists were not bound to a specific protocol and were able to use massage 
strokes and techniques deemed appropriate for each subject’s needs. However, the 
primary technique used was effleurage, which consists of applying deep flushing strokes 
to the areas of concern to the race participant.   
     It was determined that there were no significant differences among age (P = 0.90), 
time and perceived exertion among the treatment groups. Average muscle soreness was 
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rated a 4.4 among all treatment groups. Participants who received massage from student 
therapists who accumulated 950 hours of training reported significantly greater 
improvement in muscle soreness throughout the study compared with those receiving 
massage with student therapists accumulating 700 or 450 hours of training.   
     Gender had no affect on muscle soreness throughout the study. In addition, at the 24 
hour post race time, muscle soreness for the participants receiving massage from the 
student therapists who accumulated 950 hours (2.4 pain rating) of training continued to 
report significantly lower muscle soreness ratings as compared to the subjects receiving 
massage from the student therapists with 700 (3.7 pain rating) or 450 (3.6 pain rating) 
accumulated training hours. 
     Post hoc analysis at the 48 hour post race point in the study, revealed a trend for a 
lower muscle soreness rating in the group of student therapists with 950 massage training 
hours.   Results indicated a significant improvement in muscle soreness immediately after 
the 12-15 minute massage compared with pre-massage values. Immediately following 
post massage, average muscle soreness reported for all three treatment groups was 3.1. It 
was determined that the amount of therapist training impacted the effectiveness of using 
massage as a post race recovery tool. The greatest reduction in muscle soreness was 
achieved by the student therapists who had accumulated 950 hours of training compared 
with those with 700 or 450 accumulated training hours (14). 
     Wiltshire et al. (15) sought to determine if sport massage aided muscle recovery 
following exercise by increasing blood flow in order to improve lactic acid removal by 
recruiting 12 healthy males, ages 23-26 years. Subjects were in the supine position 
throughout the duration of the experiment with the forearm positioned at heart level in 
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each of the three testing conditions. Time allowed between trials for all variables being 
measured to return to original baseline levels was about 15 to 20 minutes before the 
initiation of the next trial.  
     The three experimental protocols were arranged such that 11 of the 12 test subjects 
performed all three protocols on the same day. The three experimental conditions were 
counterbalanced between subjects. Subjects were required to perform three preliminary 
maximal isometric hand grip (IHG) contractions by using a calibrated hand grip 
dynamometer with a one minute recovery between contractions. Maximum voluntary 
contraction (MVC) was the highest of the three trials. Once MVC was established, 
subjects squeezed IHG continuously for two minutes at 40% of their MVC at the 
beginning of the testing protocol. Following IHG exercise there were two types of 
recovery:  passive and active. In the passive recovery protocol, the subject laid quietly 
following the two minute IHG with their forearm at rest for 10.5 minutes. The active 
recovery protocol consisted of subjects laying quietly for 30 seconds with their forearm at 
rest. Following the 30 second rest, subjects began rhythmic forearm contractions at 10% 
of their MVC for 10 minutes. The subjects also had a duty cycle of 1:2 contraction 
relaxation coordinated with a metronome.   
     For the post IHG massage protocol, following the subject’s two minutes of IHG, the 
subject rested for 30 seconds lying quietly with their forearm at rest in which forearm 
massage started. Massage was administered by a single registered massage therapist with 
13 years of sport massage experience. Massage consisted of effleurage strokes during the 
first and last 2.5 minutes of therapy with petrissage strokes in the five interim minutes of 
therapy. 
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     Before initiating the experimental protocols all test subjects had their right hand 
heated using a hydrocollator heating pad for 10 minutes. Following the hand heating, a 
blood sample was obtained for arterial lactic acid and hemoglobin during the 
experimental protocol. 
     Heart rate was measured using standard CM5 ECG placement and mean arterial 
pressure (MAP) was measured using finger photoplethysmography, both measured beat 
to beat. The brachial artery mean blood velocity (MBV) measurements were obtained 
beat by beat on the experimental arm. A pulse Doppler ultrasound probe was used at an 
operating frequency of four MHc.   
     The results for MBV indicated an uninterrupted pulsatile flow during passive rest. 
Active rest results indicated a negative brachial artery blood velocity. Petrissage and 
effleurage massage strokes at first decreased blood velocity followed by an increase in 
blood flow velocity during the brief pauses by the massage therapist. 
     IHG strength declined over time in the subject’s ability to maintain 40% of MVC. No 
difference was detected between MAP or HR. The MAP increased more in the passive 
recovery compared to massage and active recovery, by the end of the IHG. During active 
recovery, MAP remained higher than massage during the first 2.5 minutes of post 
exercise achieving statistical significance compared to passive recovery. 
     Immediately following IHG, VO2 was noted to be greater in passive recovery than 
both active and massage recovery. Active recovery was greater than massage recovery. 
The VO2 was substantially greater in active recovery compared to both passive and 
massage recovery.  Following IHG, there were no significant differences in recovery 
conditions after four and a half minutes. Total forearm blood flow following post IHG 
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was significantly reduced in massage recovery compared to passive recovery. However, 
it was not significant compared to active recovery. Post IHG active recovery indicated no 
difference from passive recovery. Lactic acid post IHG was found to be about 17% lower 
in active recovery compared to passive recovery but was not statistically significant. 
Hydrogen did not differ between conditions. 
     It was determined that severe impairment of blood flow occurs during the massage 
stroke, resulting in a decrease of muscle blood flow in the recovery period following 
strenuous exercise. Active recovery showed similar effects. The authors stated the 
decreased blood flow is responsible for impaired lactic acid removal from the exercised 
muscle. It appears that active recovery does not improve muscle blood flow following 
exercise; but, it does appear to increase lactic acid uptake by the muscle, improving 
lactate removal from muscle tissue. The authors noted that sports massage would not be 
optimal in situations where acute bouts of repeated exercise are occurring and where 
lactic acid builds up (15). 
     Hinds et al. (16) compared a control condition against massage to determine if 
massage affected femoral artery blood flow (FABF), muscle temperature (MT), skin 
temperature, and skin blood flow (SKBF) following quadriceps exercise. The subjects 
consisted of 13 males, ages 20-22 years, who participated in an exercise bout consisting 
of three, two minute concentric quadriceps exercises followed by either three, six minute 
deep effleurage and petrissage massages or a 12 minute rest period (control). Blood 
lactate concentration (BLa), FABF, MT, heart rate, blood pressure, skin temperature, and 
SKBF were taken at baseline, immediately following exercise, and at the midpoint as 
well as the end of the massage or rest periods.  
24 
 
     The results indicated significant differences for all the variables over time due the 
exercise compared to baseline. Massage was found to not significantly elevate heart rate, 
BLa, FABF, blood pressure, or MT compared to the control. Skin temperature and SKBF 
significantly elevated after massage compared to the control. The authors concluded that 
any increases in SKBF could potentially redirect blood flow away from recovering 
muscle tissue, thus questioning the ability of massage to aid in post exercise recovery 
(16). 
     Haas et al. (17) examined the effectiveness of using immediate compared to delayed 
compressive massage-like loading on inflammatory cell infiltration as well as peak 
isometric torque recovery following eccentric type exercises. White New Zealand rabbits 
(N=18), which were skeletally mature, were used in the study by adapting peroneal nerve 
cuffs to the hind limb in order to stimulate the tibialis anterior muscles. Following a bout 
of eccentric exercise the rabbits were randomly assigned to one of the three massage-like 
compressive loading protocols for 15 minutes for four consecutive days. The first 
protocol started immediately following exercise, the second started 48 hours following 
exercise, and the third protocol consisted of no massage-like compressive loading to act 
as a control. A relationship between torque angle was gathered from 21 joint angles 
before and after eccentric exercise as well as following four consecutive days of either 
massage-like compressive loading or no massage-like compressive loading. Following 
the final treatments immunohistochemical sections as well as muscle wet weights were 
gathered. 
     The results indicated an average decrease in peak isometric torque output following 
eccentric exercise of about 38-64%. Immediate application of massage-like compressive 
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loading was determined to have the most considerable peak torque recovery. Differences 
were found in torque recovery among delayed massage-like compressive loading and 
control, immediate and delayed massage-like compressive loading, and immediate 
massage-like compressive loading and control. An immunohistochemical analysis was 
performed and indicated a 39.3%  increase  in the amount of RPN3/57 (antibody which 
detects uncharacterized antigens found on T lymphocytes,  neutrophils, platelets, and 
thymocytes)  and a 366.0% increase in CD11b (an antibody used mainly to identify 
neutrophils but it can also identify blood monocytes, macrophages, bone marrow cells, 
and other granulocytes) positive cells among the immediate and delayed massage-like 
compressive loading. The torque angle indicated a difference for immediate and delayed 
massage-like compressive loading compared to the control. Peak isometric torque angle 
was determined and indicated a rightward shift (9.8-10.2 degrees) following exercise 
compared to the pre-exercise angle. The control, immediate, and delayed massage-like 
compressive loading indicated a leftward shift in peak isometric torque angle compared 
to the pre-exercise angle. The authors concluded that immediate massage-like 
compressive loading following exercise was more beneficial than delayed massage-like 
compressive loading in balancing inflammatory cell infiltration and in recovering muscle 
function. The authors found that by delaying the administration of massage-like 
compressive loading following eccentric exercise there was a greater amount of 
infiltration of immune cells as well as a greater amount of edema (17). 
     Weerapong et al. (18) conducted a meta-analysis and evaluated three different aspects 
of massage: types of massage, possible mechanisms for effect, and effects on 
performance, recovery, or muscular injury prevention. They concluded more research is 
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needed to determine if the effects of massage are beneficial. Furthermore, the authors 
concluded that the different types of massage, the appropriate timing of massage on 
performance, recovery from injury, or as an injury prevention method all need to be 
further examined. From their research, Weerapong et al. posed the following seven 
questions to initiate further research (18):  
1. “Can massage increase blood flow, muscle temperature, neuromuscular 
excitability or muscle flexibility?”  
2. “Can massage increase performance in sprinting, jumping, or endurance athletic 
events?” 
3. “What type of massage can produce benefits?” 
4. “How long should massage be applied?”  
5. “When should athletes receive massage?”  
6. “Are the effects of massage universal or are they specific to each massage 
therapist?” 
7. “Is the cost and time for massage appropriate when a warm-up or cool-down may 
be as, or more, effective?”  
Weerapong et al. (18) suggested an additional six points on which future research studies 
on massage should consider to overcome limitations: 
1. “An appropriate control group should be provided.”   
2. “The ideal control group for a massage study should be a passive therapy 
modality. This is where the participants receive the same attention in terms of 
time from the therapists as the massage group.”  
3. “The therapists should not apply any pressure on the muscle.”  
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4. “Some physiotherapy equipment might be appropriate to incorporate in the study 
such as a sham shortwave diathermy.”  
5. “Studies should utilize a counterbalance design in order to minimize the 
difference responses of individual participants.”  
6. “Appropriate outcome measures and massage techniques should be used in the 
study.”  
Alternative Recovery Treatments on DOMS 
     Mekjavic et al. (19) recruited 24 healthy males, 20-35 years, to investigate if 
hyperbaric oxygen therapy (HBOT) would speed muscle recovery following exercise-
induced injury to the muscle. Subjects were assigned randomly to a HBOT group or a 
placebo group. Before performing the workout each subject completed a maximal 
isometric strength test on the right elbow flexor. Following the maximal isometric 
strength test the subjects then performed the workout which induced DOMS. The 
workout consisted of a high force eccentric workout using the elbow flexor muscle group. 
Following the workout the subjects were exposed to either a normoxic (0.2 ATA) mixture 
or a hyperoxic (2.5 ATA) mixture for an hour over seven continuous days. During one of 
their oxygen therapies, each subject had a transcutaneous PO2 electrode which was 
attached over the biceps brachii via the skin in order to determine the amount of tissue 
oxygenation by the oxygen therapy. The subjects used a VAS to rate their perceived 
muscle soreness from “no pain at all” to “worst pain I could possibly feel.” 
     The results indicated a significant decrease in isometric strength from pre-exercise to 
the post-exercise in both the placebo and HBOT groups. Over the recovery period no 
significant difference was found in the rate of muscle strength recovery between the 
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groups. No significant difference between the groups was found in perceived soreness 
with soreness levels peaking 48 hours post exercise. Additionally, increases in arm 
circumference caused by exercise were similar between groups. The authors concluded 
that HBOT was not effective in the treatment of DOMS and the use of this therapy is not 
warranted and athletes should be discouraged from using it (19). 
     Pointon et al. (20) examined the effects of cold water immersion (CWI) on recovery 
following simulated collision sport exercise. The study consisted of 10 male rugby 
players, ages 19-23 years, who performed three sessions including two, 30 minute 
intermittent sprint exercises (ISE) consisting of 15 meter sprints every minute followed 
by self-paced exercise bouts of walking, hard running, or jogging making up the rest of 
the minute. Randomly incorporated into the ISE were three testing conditions: no 
tackling with passive recovery (the control), tackling with passive recovery, and tackling 
with a 20 minute CWI recovery. During every sixth rotation, the test subjects received 
shoulder led tackles to the lower body while performing five, 10 meter sprints on each 
exertion. The variables recorded in the study were sprint times and distances covered in 
the ISE, electromyogram, voluntary activation, maximal voluntary contraction, and 
perceived soreness. Venous and capillary blood markers were measured before and after 
exercise to establish baseline measures, immediately following recovery as well as two 
and 24 hours post recovery for metabolites indicating muscle damage. 
     Results indicated tackling with CWI significantly increased voluntary action, 
electromyogram, and maximal voluntary contraction immediately following recovery. 
Tackling with CWI had no effect on the elevation of DOMS markers but blood lactate 
was reduced significantly following recovery compared to tackling with passive 
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recovery. The results further indicated CWI reduced perceived muscle soreness two hours 
following recovery compared to tackling with passive recovery. The authors concluded 
that with bodily collision, the ability to perform exercises decreases, CWI aids in an 
accelerated recovery of voluntary action, electromyogram, and maximal voluntary 
contraction, as well as promotes an improved perception of muscle soreness and 
contraction following exercise which is collision-based (20). 
     Mawhinney et al. (21) sought to determine if cold (eight degrees Celsius) and cool (22 
degrees Celsius) water immersion affects cutaneous and femoral artery blood flow 
following exercise. The study consisted of 12 men, age 21-30 years, who completed a 
cycle test at 70% of the subject VO2 max until the desired core body temperature of 38 
degrees Celsius was achieved. Once the desired core body temperature was achieved, the 
subjects were immersed into either cold or cool water while semi-reclined up to the iliac 
crest for 10 minutes or participated in a seated rest (control). The variables measured in 
the study before immersion, and up to 30 minutes following immersion were thigh skin 
and rectal temperature, superficial and deep muscle temperature, blood flow to the calf 
and thigh using laser Doppler flowmetry, as well as blood flow of the superficial femoral 
artery using duplex ultrasound. Calculated variables during the study included vascular 
conductance indices such as flux and blood flow, heart rate, and mean arterial pressure. 
     Results of the study indicated similar rectal temperature reductions (a range of 0.6 
degrees to 0.7 degrees Celsius) in all three of the trials. During recovery following 
exercise, the average skin temperature of the thigh was 25.4 degrees for the cold water 
trial, 28.2 degrees for the cool water trial, and 33.8 degrees for the control trial. Similarly, 
the lowest recorded recovery muscle temperature during the study was found in the cold 
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water trial. Conductance of the femoral artery 30 minutes following immersion in both 
the cold and cool water trials was lower in temperature (about 55%) compared to the 
control trial. The study also revealed greater cutaneous vasoconstriction in both the calf 
and thigh during and following cold, as well as cool water immersion trials compared to 
the control. The authors concluded that colder water temperature could perhaps be more 
effective in treating damage caused by exercise and in rehabilitating injuries due to a 
greater reduction in muscle temperature, not muscle blood flow (21). 
     Wheeler and Jacobson (22) assessed the effects of whole body vibration (WBV) on 
delayed onset muscle soreness (DOMS), explosive power, and flexibility following 
induced DOMS. The study included 10 men and 10 women, ages 19-23 years, randomly 
assigned to either a control or experimental group. Subjects performed baseline 
measurements prior to DOMS-induced exercise for explosive power, VAS, hamstring 
flexibility, and lower back flexibility. These same variables were measured immediately 
following exercise and again immediately following treatment. Following the initial 
testing session, the subjects reported back to the lab for four consecutive days at the same 
time of day for additional data collection. These sessions included the subjects 
participating in a VAS, vertical jump assessment, and a sit and reach. Following the 
completion of the assessments, the subjects in the treatment group then spent 10 minutes 
on the WBV machines while those in the control group spent 10 minutes walking on a 
treadmill. Following the ten minutes of either WBV or treadmill walking VAS, vertical 
jump, and the sit and reach assessments were again repeated and recorded. 
     When comparing pre and post-assessments of explosive power, DOMS, and flexibility 
between groups or within groups, no significant difference was found. When comparing 
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light exercise to WBV, no significant difference was found for explosive power, DOMS, 
or flexibility. The authors concluded that WBV is as equally effective as light exercise as 
a treatment modality for lowering the symptoms of DOMS, qualifying it as a recovery 
option to be used in addition to other current DOMS treatments (22).  
  Cantanese (23) sought to determine if skeletal muscle damage, DOMS, as well as 
markers of muscle inflammation were affected by external counterpulsation (ECP). Prior 
to this study, ECP had been used primarily in treating cardiac patients by compressing the 
patient’s lower extremities during diastole increasing coronary perfusion and aiding 
venous return. Five males and five females, ages 18-43 years, participated in two 20 mile 
runs completed at 70% of their VO2 max, once under a treatment trial and once under a 
control trial. Variables measured were lactate dehydrogenase (LDH), C- reactive protein 
(CRP), creatine kinase (CK), and perceived leg pain. The variables were measured before 
the run, immediately following the run, and daily for five consecutive days on both the 
control and treatment conditions. Additionally, in order to control for effects of ECP five 
more subjects, ages 24-28 years, remained inactive while receiving five consecutive days 
of ECP treatment. 
     The results indicated no significant changes between the 10 subjects and the control 
group receiving ECP treatment only in pain, CRP, CK, and LDH. Subject’s pain, LDH, 
and CRP significantly decreased following ECP treatment compared to the control. The 
author found that CK remained significantly elevated three days longer in the ECP 
treatment group compared to the control. Females experienced a significant difference in 
CK and CRP whereas the males did not. In both males and females a 20% reduction in 
pain occurred as a result of the ECP treatment, however, females did experience pain for 
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one additional day compared to the males. Females also experienced a 20% increase in 
LDH compared to the males. The males experienced a significant change in LDH on day 
four of the control run, and immediately following the ECP treatment run. 
     The author concluded ECP treatment decreased inflammation, LDH elevation, and leg 
pain in runners following a 20 mile run. When comparing the treatment run to the control 
CK levels were found to remain significantly elevated however, it was determined ECP 
alone did not cause a significant increase in CK (23). 
Effects of Intermittent Pneumatic Compression (IPC) Treatments 
     Konstantinos and Knaggs (24) examined three intermittent pneumatic compression 
(IPC) sequences and their effects on patients with peripheral arterial disease (PAD). The 
three IPC sequences examined consisted of separated IPC deliveries to the foot and calf, 
and simultaneous compressions on both the foot and calf.  These three sequences were 
used to determine duration and amplitude decay of acute leg inflow enhancement. The 
experimental design was a cross sectional study which included patients with PAD and 
intermittent claudication resulting from either superficial femoral artery occlusion or 
severe stenosis. The control group consisted of 20 subjects, seven females and 13 males, 
ages 44-78 years, with no medical history of cardiovascular disease, claudication, and 
with normal circulation. The experimental group consisted of 22 subjects, nine females 
and 13 males, ages 50-70 years, diagnosed with intermittent claudication. The 
experimental and control groups were matched according to age and gender and were 
treated with IPC.  
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     The baseline volume flow was measured and was determined to be higher in the 
experimental group without reaching significance. The peak volume flow measured with 
any IPC mode applied was found to be not significantly different between the 
experimental and control groups. Additionally, the pulsatility index was found to be 
lower in the limbs in the experimental group than in the control. It was also found to be 
lower in the experimental group at the baseline level, five seconds after the delivery of 
IPC, and throughout the 5 to 50 seconds of its determination with IPC.  
     Flow enhancement was longer in the simultaneous IPC on the foot and calf versus the 
foot only in both the experimental and control groups. Experimental and control group 
decay rates of volume flow enhancement indicated a significant decline. Conclusions 
drawn from the study indicated that the arteriovenous pressure gradient, nitric oxide, and 
peripheral sympathetic auto-regulation are likely to be active following IPC 
administration (between 0 and 20 seconds). During the mid-phase (between 20 and 35 
seconds) the arteriovenous pressure gradient and peripheral sympathetic auto-regulation 
were the only active factors, nitric oxide being excluded. The authors concluded that the 
arteriovenous pressure gradient is perhaps the most effective flow enhancer found in the 
late phase of flow decay (between 35 and 50 seconds) (24). 
     Moseley et al. (25) undertook a broad systematic review of common and conservative 
therapies to treat secondary arm lymphoedema which included complex physical therapy, 
limb exercises and limb elevation, oral pharmaceuticals, manual lymphatic drainage, 
compression bandaging and garments, low level laser therapy, and pneumatic pumps. The 
study included participants who had a formal diagnosis of chemotherapy-induced and/or, 
radiotherapy-induced, secondary arm lymphoedema following breast cancer surgery 
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regardless of whether the surgery was a total or partial mastectomy. The study excluded 
participants who had primary lymphoedema or recurrent cancer. 
     Of the studies being reviewed for pneumatic pump therapy, the authors found better 
results in volume reduction occurred when the pneumatic pump was combined with other 
therapies such as self-massage, manual lymphatic drainage, and compression garments 
compared to only using the pneumatic pump as therapy. Additionally, in the reviewed 
studies, the pneumatic pump demonstrated the ability to maintain initial volume 
reductions in the patients who continued with pneumatic pump therapy (25). 
     Partsch (26) discussed different therapeutic modalities used in reducing edema and 
aiding in venous leg ulcer healing. He emphasized the value intermittent pneumatic 
compression (IPC) has in the treatment of limb edema and the associated skin changes 
frequently seen on immobile patients’ legs. Partsch discussed how commonplace 
compression stockings and compression bandages are not as effective in the treatment of 
immobile patients. This is because compression stockings and bandages are not as 
efficient in supporting the impaired veno-lymphatic pump but however do impede the leg 
from swelling. Comparatively, IPC actively compresses the immobile patient’s limb 
producing cyclical pressure waves which mimic the resting and working pressures which 
are applied by compression bandages. Partsch further stated that IPC not only reinforced 
the veno-lymphatic pump that is critical in restoring damaged microcirculation of the skin 
but also reduces limb swelling. Partsch makes the clarion call that using IPC as a 
treatment modality is underused, particularly in patients who are immobile and/or bound 
to a wheelchair (26). 
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     Avery et al. (27) presented a case study involving a five month old male diagnosed 
with congenital lymphedema in the right lower limb. The five month old patient had been 
successfully treated using intermittent pneumatic compression (IPC) therapy. The authors 
discussed various treatment options and the pros and cons of each individual treatment in 
which IPC is discussed. One of the authors, Dr. Laura Jacobs, defined pneumatic 
medicine as using an airtight sleeve made of fabric to apply pressure to an extremity. The 
compression device having been calibrated by a physician for both time and pressure is 
then used to inflate the fabric sleeve in a rhythmic fashion. Moderate external pressure 
compresses the limb and creates a mechanical force which in turn, decongests the tissues 
and improves not only lymphatic return but venous return as well. 
     The authors referenced a study which claimed IPC therapy to be a proven, safe, and an 
effective modality in the treatment of lymphedema in patients of all ages (28). In 
comparing IPC to complex physical therapy (CPT), there are several advantages in using 
IPC over CPT. One advantage being the decongesting of the limb through the sequential 
pumping style of distal to proximal compared to the static nature of CPT treatment 
methods. The second advantage of using IPC over CPT is the pumping action, duration, 
and pressure of the sequential pneumatic compression is both consistent and reproducible 
whereas CPT is subject to human inconsistency. The third advantage is IPC treatments 
can easily be self-administered on a daily basis and at home whereas CPT requires a 
specially trained therapist to administer the therapeutic treatment. The authors cautioned 
to rule out deep vein thrombosis by using a duplex ultrasound prior to the initiation lower 
limb therapy. The reason being that compression coupled with a deep vein thrombosis 
could lead to a pulmonary embolism. The authors concluded that IPC is effective, safe, 
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and underutilized in reducing and treating children diagnosed with congenital 
lymphedema (27). 
     Labropoulos et al. (29) sought to determine if the use of intermittent pneumatic 
compression (IPC) in patients with critical limb ischemia would increase skin, 
gastrocnemial, collateral arterial, and popliteal blood flow. All patients included in the 
study had at least two-level disease diagnosed by angiography. The average age of the 
study participants was 74 years. Using laser Doppler fluxmetry and duplex ultrasound 
scans, 20 limbs which had been diagnosed with critical limb ischemia in 20 patients were 
assessed in a semi-erect position before, during, and following IPC treatments. Of the 20 
limbs, 14 of the limbs had been identified as inoperable, and six had been identified as 
marginal for reconstruction. One pneumatic cuff was placed on the foot and the second 
on the calf using a maximum inflation pressure of 120 mmHg with the compression cycle 
set at three seconds with three cycles per minute. The flow volumes measured in the 
study consisted of the popliteal, genicular collateral artery and the medial gastrocnemial 
with the skin blood flow being measured at the same time on the dorsum of the foot. 
     The results indicated a significant increase in the flow of all three arteries compared to 
baseline levels with the highest change found in the popliteal, with the gastrocnemial and 
the collateral artery following suit respectively. Following the discontinuance of the IPC, 
blood flow returned to baseline values which can be attributed to the diameter of the 
arteries not changing. The increase in skin blood flow was also significant. The results 
also indicated of the 20 limbs measured there were two which did not increase in arterial 
or in skin blood flow. This was attributed to a significant popliteal vein reflux and both of 
the two limbs were amputated not long after the completion of the study. The authors 
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concluded that IPC augments skin, muscular, axial, and collateral blood flow in patients 
diagnosed with critical limb ischemia. However, patients with significant venous reflux 
may not benefit from using IPC. The authors further concluded that IPC may prove 
beneficial for patients who may not be candidates for revascularization and that IPC 
enhances blood flow through augmenting the arterio-venous pressure gradient (29). 
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CHAPTER III 
METHODS 
     An experimental design was used to test the effectiveness of the NT recovery unit. The 
independent variable was the NT recovery treatment vs. the control condition. The 
dependent variables were the biochemical marker associated with inflammation; CRP; 
and DOMS. The study was delimited to trained long distance runners capable of running 
20 miles at 70%  or above of their maximum heart rate.  
Subjects 
     Ten subjects, five trained males and five trained females, age 20 to 53 years, who 
attended Cleveland State University (CSU) or lived in the surrounding Cleveland, OH 
area were enrolled. The subjects were obtained through a convenience sample, by 
recruiting volunteers from local running and triathlon clubs, and individuals from the 
CSU women’s cross country team. The subjects consisted of marathoners, ultra 
marathoners, ironman triathletes, and collegiate athletes. All potential subjects completed 
an AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire (30, 
Appendix B) to measure potential health risk factors for people engaging in an exercise 
program. Subjects needed to be in the “Low Risk” category after completing the 
screening questionnaire. Subjects included in the study were trained and capable of 
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running 20 miles at 70% of their VO2 max. Subjects were excluded from participating in 
the study if they had a history of musculoskeletal, cardiovascular, circulatory, or any 
other health problems which may have put them at risk if they participated in the study.  
     All subjects were asked to refrain from other physical activity, flu shots or other 
immunizations, and other recovery treatments such as stretching, ice baths, or consuming 
anti-inflammatory medications such as NSAIDS during the six days they participated in 
the study, as well as 48 hours before the start of the six days. Subjects were also not 
permitted to participate in the study if they had a cold, and had to wait until they had 
completely recovered from their cold as inflammation levels would not be a valid 
indicator of exercise inflammation. 
Procedures 
     Subjects who qualified to participate in the study signed an informed consent form 
(Appendix C) approved by the Institutional Review Board at CSU (Appendix D). 
Subjects who qualified for the study were required to perform a graded VO2 max test to 
establish running intensity (70 % VO2 max) for the running trial. A cross-over design was 
implemented and subjects were randomly assigned to either the treatment run or the 
control run for their first 20 mile run to avoid order effect. The second run was completed 
three to four weeks after completing the first run. Test participants were asked to refrain 
from training 48 hours prior to their 20 mile run. Procedures for this study were based on 
a previous study conducted in the human performance lab at CSU (23). 
     Immediately before each participant started their 20 mile run, baseline data was 
collected. Nude weights were taken immediately before and after the run using a 
physician’s beam scale, and height using a stadiometer. CRP blood samples were 
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obtained via venipuncture using SST BD Vacutainer serum collection tubes (3.5 mL). 
Blood samples sat for 30 minutes to coagulate then were spun down using a centrifuge at 
2900 RPM for 10 minutes.  
     Once the baseline measurements were acquired, the run started on a premeasured 
course. The test subjects completed a 20 mile run at an intensity of 70% or higher of their 
VO2 max. Each runner wore a Polar heart rate monitor to monitor the running intensity 
(heart rate corresponding to 70% VO2 max obtained during the max test). Subjects were 
provided water, or their preferred liquid, to drink during competition or training, 
according to each participant’s specific hydration routine to prevent dehydration.  Fluid 
intake was monitored and recorded for each runner. Immediately after the 20 mile run, 
another venous blood sample was taken from the anticubital vein for CRP. Perceived pain 
was assessed using the Management of Cancer Pain Scale Test (31, Appendix E); body 
weight was again obtained to determine fluid loss from dehydration and to calculate 
sweat rate. Subjects who completed the treatment run received treatment using the NT 
recovery system immediately following blood sampling.  
     All treatment subjects received the same treatment, one hour of NT at an intensity 
setting of 10 (90mmHg for cell 1 and cell 5 and100 mmHg for cells 2-4) with a 
compression duration of 30 seconds. The NT recovery system is a boot which is divided 
into five sections and in each of these five sections there are inflatable bladders or cells. 
Cell one is located on the foot and each cell continues up the leg to the top of the thigh 
where cell five is located. Each bladder or cell inflates or compresses the limb for 30 
seconds. NT recommends that for athletes, the intensity setting be at 10 (intensity settings 
range from 1-10) to ensure the best results for recovery. The amount of pressure exerted 
on the limb at an intensity setting of 10 in each of the cells is as follows: cell one and cell 
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five - 90mmHg; cells two, three, and four - 100mmHg. This inflation is synchronized to 
mimic a massaging action and to increase blood flow. Each leg was treated 
simultaneously. 
     For five consecutive days after the run, blood samples were obtained for CRP. 
Perceived pain was recorded and subjects used the NT device for five consecutive days. 
Subjects who did not receive treatment after the 20 mile run will underwent the same 
protocol except for the NT treatment, and were able to leave the lab after CRP and pain 
were measured.  
     The second 20 mile run was held approximately three to four weeks after the first 20 
mile run to ensure complete recovery. Subjects who were previously in the treatment trial 
participated in the control trial, while those who were previously in the control trial 
participated in the treatment trial. Procedures for the second 20 mile run were exactly the 
same as those in the first 20 mile run. 
Data Analysis 
     Descriptive statistics were acquired on all measures. A repeated measures ANOVA 
was used to assess recovery within a treatment group, whereas a two-way ANOVA was 
used to assess treatment differences due to NT recovery treatment vs. control on CRP and 
subjective pain across the five days. SPSS (version 18) was used for all analyses with 
0.05 used as the level of significance. Paired sample t-tests were used to specify 
differences across the five days. 
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CHAPTER IV 
RESULTS & DISCUSSION 
Results 
     Ten subjects, five males and five females participated in the study to determine the 
effectiveness of the NT compression system for recovery after a 20 mile run. As 
expected, the males were taller, heavier, and had a higher VO2 max than the female 
runners (Table 1).  
Table 1. Characteristics of the subjects. 
Characteristics Males (N=5) 
Mean ± SD 
Females (N=5) 
Mean  ± SD 
Total Group (N=10) 
Mean  ± SD 
Age (years) 41.2 ± 10.6 36.2 ± 12.4 38.7 ± 11.2 
Height (cm) 176.7 ± 4.5 164.6 ± 5.2 170.7 ± 7.8 
Weight (kg) 74.1 ± 4.5 60.5 ± 5.2 67.3 ± 8.5 
VO2 Max (ml·min·kg) 54.1 ± 4.5 48.6 ± 6.0 51.4 ± 5.8 
 
   Males were found to be significantly taller and weigh significantly more than the 
female runners. No significant difference was found in age or VO2 max between genders 
(Table 2). 
 
43 
 
 
Table 2. Gender comparison of age, height, weight, and VO2 max of the subjects. 
Condition (N=10) Mean ± SD P - value 
Male vs. Female Age 41.2 ± 10.6 vs. 36.2 ± 12.4 .608 
Male vs. Female Height 176.7 ± 4.5 vs. 164.6 ± 5.2 .046* 
Male vs. Female Weight 74.1 ± 4.5 vs. 60.5 ± 5.2 .013* 
Male vs. Female VO2 Max 54.1 ± 4.5 vs. 48.6 ± 6.0 .254 
* Indicates significance 
     There was no significant difference in mean weight loss, fluid intake, sweat rate, heart 
rate, percentage of maximum heart rate, or percentage of maximum VO2 max between 
runs (Table 3). There was, however, a significant difference (P = .038) in running time 
when comparing the control run against the treatment run. This was likely due to 
differences in weather conditions.  
Table 3. Comparison between the control run and the NT treatment run. 
Condition (N=10) Control (Mean ± SD) Treatment (Mean ± SD) P - value 
Weight Loss (kg) 1.17 ± .74 1.32 ± .72 .370 
Fluid Intake (ml) 1087.3 ± 505.7 1307.8 ± 728.2 .308 
Sweat Rate (L/hr) .37 ± .28 .40 ± .23 .649 
Heart Rate (bpm) 143.9 ± 10.8 147.8 ± 12.8 .213 
% Max Heart Rate (bpm) 79.8 ± 6.5 81.8 ± 5.6 .222 
% VO2 Max (ml/min/kg)** 72.3 ± 9.0 69.8 ± 10.9 .082 
Running Time (min) 196.2 ± 28.7 204.8 ± 31.1 .038* 
* Indicates significance 
** Estimated from American College of Sports Medicine (ACSM) formula 
     To determine if the first run had an effect on the second run, a repeated measures 
ANOVA was used comparing all of the first runs with all of the second runs. The results 
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indicated no significant difference (P > 0.05) in any variables except for in one of the pain 
ratings. When comparing the pain experienced immediately following the first run versus 
second run, runners indicated they experienced more pain following the second run (4.9 
on VAS) compared to the first run (3.7 on VAS). This slight increase in pain on the 
second run occurred regardless of whether the run was a treatment run or a control run. 
CRP 
     No significant difference between the control run and the treatment run was found for 
CRP (Table 4). The subjects recovered by day four while using the NT device whereas 
the control had still not recovered by day five. However, this difference was not 
significant. 
Table 4. Comparing baseline CRP values to post run CRP values. 
Condition (N=10) Mean ± SD P - value Condition (N=10) Mean ± SD P - value 
Control Post Run 2.90 ± 0.00 ---- Treatment Post Run 2.90 ± 0.00 ---- 
Control Day 1 7.06 ± 3.39 .004* Treatment Day 1 7.95 ± 4.08 .004* 
Control Day 2 5.92 ± 4.20 .049* Treatment Day 2 4.85 ± 1.95 .012* 
Control Day 3 4.80 ± 4.90 .251 Treatment Day 3 3.19 ± 0.72 .234 
Control Day 4 3.68 ± 2.33 .317 Treatment Day 4 2.94 ± 0.13 .343 
Control Day 5 3.17 ± 0.85 .343 Treatment Day 5 2.90 ± 0.00 ---- 
Normal = 2.9 mg/L 
* Indicates significant difference from baseline 
     The results indicated no significant difference in CRP levels between the control run 
and treatment run. However, the subjects recovered one day earlier when using the NT 
device compared to the control. Statistically this may not be significant, but a full day 
recovery for a professional athlete is important (Figure 2).  
 
45 
 
 
Figure 2. Control Run vs Treatment Run. 
CRP Gender Comparisons 
     When the males used the NT device, there were significant increases in CRP from 
baseline on days one and two. The results indicated the males had recovered by day three, 
compared to the control, who had still not recovered by day five (Table 5). However, this 
difference was not significant. 
Table 5. Comparing male baseline CRP values to each recovery day. 
Condition (N=5) Mean ± SD P - value Condition (N=5) Mean ± SD P -value 
Control Post Run 2.90 ± 0.00 ---- Treatment Post Run 2.90 ± 0.00 ---- 
Control Day 1 7.00 ± 3.72 .069 Treatment Day 1 7.76 ± 3.53 .037* 
Control Day 2 6.98 ± 5.60 .178 Treatment Day 2 4.42 ± 1.11 .038* 
Control Day 3 6.32 ± 6.90 .329 Treatment Day 3 2.94 ± 0.09 .374 
Control Day 4 4.38 ± 3.31 .374 Treatment Day 4 2.90 ± 0.00 ---- 
Control Day 5 3.44 ± 1.21 .374 Treatment Day 5 2.90 ± 0.00 ---- 
Normal = 2.9 mg/L 
* Indicates significant difference from baseline 
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     No significant difference was determined from baseline in either the control run or the 
treatment run among the female runners. Additionally, the females recovered in the same 
amount of time (by day four) regardless if they were using the NT device (Table 6). 
Table 6. Comparing female baseline CRP values to each recovery day. 
Condition (N=5) Mean ± SD P - value Condition (N=5) Mean ± SD P -value 
Control Post Run 2.90 ± 0.00 ---- Treatment Post Run 2.90 ± 0.00 ---- 
Control Day 1 7.12 ± 3.48 .053 Treatment Day 1 8.14 ± 4.99 .078 
Control Day 2 4.86 ± 2.37 .138 Treatment Day 2 5.28 ± 2.62 .112 
Control Day 3 3.28 ± 0.85 .374 Treatment Day 3 3.44 ± 1.00 .293 
Control Day 4 2.98 ± 0.18 .374 Treatment Day 4 2.98 ± 0.18 .374 
Control Day 5 2.90 ± 0.00 ---- Treatment Day 5 2.90 ± 0.00 ---- 
Normal = 2.9 mg/L 
* Indicates significant difference from baseline  
Pain 
     A significant difference from the baseline pain rating occurred from the time of the 
post run until day three for both the control run and treatment run. During the treatment 
run trial however, the test subjects had no pain on day five while using the NT device 
compared to the control in which the subjects still had some pain on day five (Table 7). 
Table 7.  Comparing baseline pain ratings to post run pain ratings. 
Condition (N=10) Mean ± SD P - value Condition (N=10) Mean ± SD P -value 
Control Post Run  4.10 ± 2.42 .000* Treatment Post Run  4.70 ± 1.42 .000* 
Control Day 1 2.90 ± 1.51 .000* Treatment Day 1 3.00 ± 1.76 .000* 
Control Day 2 2.35 ± 1.38 .000* Treatment Day 2 2.15 ± 1.86 .005* 
Control Day 3 0.95 ± 1.26 .041* Treatment Day 3 1.00 ± 1.05 .015* 
Control Day 4 0.40 ± 0.84 .168 Treatment Day 4 0.20 ± 0.48 .223 
Control Day 5 0.10 ± 0.32 .343 Treatment Day 5 0.00 ± 0.00 ---- 
Scale 0 (no pain) - 10 (worst pain possible) 
* Indicates significant difference from baseline (no pain) 
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Pain Gender Comparisons 
     In males, the pain ratings during the control trial were significantly elevated from 
baseline until day three while the treatment trial ratings were only significantly elevated 
until day one. This indicates that the males had significant pain through day two on the 
control run compared to significant pain only through day one on the treatment run when 
using the NT device (Table 8). 
Table 8. Comparing male baseline pain ratings to post run pain ratings. 
Condition (N=5) Mean ± SD P - value Condition (N=5) Mean ± SD P -value 
Control Post Run  3.60 ± 2.88 .049* Treatment Post Run 4.40 ± 1.82 .006* 
Control Day 1 3.30 ± 1.92 .019* Treatment Day 1 2.60 ± 1.95 .041* 
Control Day 2 2.50 ± 2.00 .049* Treatment Day 2 2.10 ± 2.25 .105 
Control Day 3 1.10 ± 1.67 .216 Treatment Day 3 1.00 ± 1.41 .189 
Control Day 4 0.40 ± 0.89 .374 Treatment Day 4 0.30 ± 0.67 .374 
Control Day 5 0.00 ± 0.00 ---- Treatment Day 5 0.00 ± 0.00 ---- 
Scale 0 (no pain) - 10 (worst pain possible) 
* Indicates significant difference from baseline (no pain) 
     The female pain ratings indicated significantly elevated pain ratings from baseline in 
the treatment trial until day three compared to the control trial where pain ratings were 
only significantly elevated from baseline until day two. This indicates that the females 
had higher amounts of pain while using the NT device (Table 9). 
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Table 9. Comparing female baseline pain ratings to post run pain ratings. 
Condition (N=5) Mean ± SD P - value Condition (N=5) Mean ± SD P -value 
Control Post Run  4.60 ± 2.07 .008* Treatment Post Run  5.00 ± 1.00 .000* 
Control Day 1 2.50 ± 1.00 .005* Treatment Day 1 3.40 ± 1.67 .010* 
Control Day 2 2.20 ± 0.45 .000* Treatment Day 2 2.20 ± 1.64 .040* 
Control Day 3 0.80 ± 0.84 .099 Treatment Day 3 1.00 ± 0.71 .034* 
Control Day 4 0.40 ± 0.89 .374 Treatment Day 4 0.10 ± 0.22 .374 
Control Day 5 0.20 ± 0.45 .374 Treatment Day 5 0.00 ± 0.00 ---- 
Scale 0 (no pain) - 10 (worst pain possible) 
* Indicates significant difference from baseline (no pain) 
Temperature Conditions During the 20 Mile Runs 
     The temperature of the first run was compared to the temperature of the second run to 
determine if a difference occurred. There was a significant difference (P = .030) between 
the temperatures of the first run (6.4 ºC) compared to the second run (2.8 ºC). The 
temperature of the control run (4.8 ºC) was compared to the temperature of the treatment 
run (4.4 ºC) to determine if a difference occurred. No significant difference (P = .855) 
was found in temperature between the control and treatment runs. 
Discussion 
     C- reactive protein levels peaked on Day 1 for both the control and treatment runs and 
then gradually decreased until they returned to baseline by day 4 (NT) and day 5 
(control). This is consistent with the research performed by Fallon (32) who stated that 
the acute phase response has been suggested to relate to skeletal muscle damage when 
associated with exercise. The acute phase response is a response of certain proteins in the 
blood plasma whose concentrations either increase or decrease due to inflammation. C- 
reactive protein is reported to be the most plentiful of the acute phase proteins and has 
been reported to be elevated following exercise, especially when muscle damage has 
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occurred (32, 33). C- reactive protein remained higher than baseline until Day 5 for the 
control run but remained higher than baseline only until day 4 for the treatment run. 
These results are consistent with the literature (32, 33). 
     A study performed by Milias et al. (5) found no significant differences in the 
inflammatory markers CRP, complement C3, and fibrinogen following eccentric exercise. 
Simpson et al. (34) also found no significant difference in CRP even after a hill race 
although muscle damage was present. This suggests that inflammation may not 
correspond to muscle damage. The results of the present study support this. 
     The results in the present study conflict with those found in a previous study by 
Cantanese (23) in which the same experimental protocol was used, except external 
counter pulsation (ECP) was the treatment modality. In that study, ECP helped the 
runners recover two days faster than in the control trial which was statistically significant. 
Additionally, only the females in the ECP study experienced a significant difference in 
CRP whereas in the current study, it was the males who responded to the treatment. The 
major differences between treating the runners with ECP compared to NT were the cuff 
pressure and compression duration. The maximum ECP cuff pressure was 6 psi and the 
maximum NT cuff pressure was 2.1 psi. The ECP compression duration only lasted 
during diastole (about a second) whereas the NT compression lasted about one minute. 
The difference in cuff pressure and compression may have contributed to why we did not 
obtain the same results with the NT device as Cantanese (23) did with the ECP study. 
     When comparing the first run against the second run for both males and females, CRP 
peaked on day one for both runs but the peak on the second run was 1.4 mg/L less than 
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the peak on the first run. This is also consistent among gender with the second run 1.7 
mg/L less CRP among males and 1.0 mg/L less CRP among females compared to the first 
run, suggesting rapid adaptation. In a study by Clarkson et al. (35), less muscle damage 
was produced when the same exercise was performed several months later due to 
adaptation. Rapid adaptation could potentially explain smaller responses seen after 
downhill running due to preadaptation. The exact etiology of this adaptation is not 
known. In the study by Clarkson et al. (35), one group exercised six weeks apart and after 
the second bout of exercise DOMS, and flexed arm angle responses were found to be 
significantly smaller. This may explain the blunted peak CRP response on the second run 
for both males and females, and suggests a longer span of time needed between the 
treatment and control runs (six weeks or longer) to mitigate long-term adaptations. 
     Concerning gender, the males recovered about two days faster using the NT device 
compared to control but the females did not recover faster using the NT device compared 
to control. When comparing the male CRP values to baseline, the males had a significant 
difference from baseline on day one and two when using NT compared to the control (no 
significant difference from baseline) suggesting NT made the inflammation worse. The 
CRP values compared to baseline among females revealed no significant difference from 
baseline suggesting there was no benefit in using NT. Regarding gender differences, there 
has been some debate as to the existence of sex differences in exercise-induced muscle 
damage and repair based on an assumption that estrogen levels exert a response that may 
enhance the recovery of skeletal muscle to damaging exercise. These assumptions are 
based on estrogen’s potential ability to stabilize the cells of skeletal muscle during 
exercise due to estrogen’s antioxidant properties (36). Studies that assess DOMS or pain 
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usually do not find sex differences (37, 38, 39) and those that do site differences between 
men and women are inconsistent (36). Another study demonstrated that there were no 
differences in sex when comparing untrained men and women in muscle fatigue or other 
changes in muscle function parameters during eccentric exercise (40). The results from 
the present study, however, indicate a difference in gender response to the NT recovery 
device adding to the inconsistency of whether gender differences exist. 
     Previous physical conditioning is the most effective technique to speed up the 
recovery process after strenuous exercise (41). The majority of subjects involved in the 
study were trained marathoners, ultramarathoners, triathletes, and collegiate athletes. Two 
subjects (one male and one female) did not elicit a CRP response following the protocol 
on either the control run or treatment run. The level of training (perhaps due to interval 
training) and running efficiency of the subjects may possibly have contributed to the lack 
of an inflammatory response, limiting the effectiveness of the NT recovery device, which 
could influence the results of the study. 
Pain 
     When comparing pain ratings to baseline, the results indicated no significant 
difference between NT and control. The male pain ratings were significant from baseline 
until day one in the treatment trial compared to the control which was significant from 
baseline until day two, indicating NT helped ease the pain one day sooner for the males. 
The females exhibited the opposite. The female pain ratings were significant from 
baseline until day two in the control trial compared to the treatment which was significant 
from baseline until day three, indicating the females had more pain while using NT. 
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     Perceived pain in all 10 subjects while using the NT device was lower compared to the 
control. This is consistent with a study by Hilbert et al. (42) in which they tested the 
physiological and psychological effects of massage on DOMS. They concluded massage 
may provide psychological benefits as it reduces the intensity of soreness which is 
commonly associated with DOMS (42). Many subjects, both male and female, stated that 
while using the NT device they kept waiting for the pain associated with DOMS to come 
a day or two after the run and they stated it never came. These statements are subjective 
and based on self-reported data.  
     When comparing the first run to the second run for pain there was a significant 
difference between the two runs. The subjects in the second run experienced less pain 
compared to the first run. However, when comparing the first run to the second run in 
terms of gender, no significant difference was found. For males, by day two the second 
run recorded lower pain levels compared to the first run while the females recorded a 
higher level of pain in the second run compared to the first run.  
Temperature 
     Temperature and weather may have played a role in the present study. Testing started 
on October 21, 2013 and ended January 18, 2014. Subjects started the study in ideal 
running conditions but as the study progressed subjects ran in cooler conditions. A 
significant difference between the temperatures of the first run compared to the second 
run was found. This may suggest why the second run was significantly slower compared 
to the first in Table 3. No significant difference was found in temperature between the 
control and treatment runs. 
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CHAPTER V 
SUMMARY & CONCLUSION 
     Ten trained runners ran two 20 mile runs and each subject participated in the control 
and treatment runs. Trails were randomly counterbalanced to provide a safeguard against 
order effect. Muscle soreness was induced on both runs to elicit a CRP response and 
subjects were asked to rate their pain immediately following the run and each day after 
for five days.  
     The subjects recovered by day four while using the NT device whereas the control had 
still not recovered by day five. However, this difference was not significant. The results 
indicated the males had recovered by day three, compared to the control, who had still not 
recovered by day five. However, this difference was not significant. No significant 
difference was determined from baseline in either the control run or the treatment run 
among the female runners and the females recovered in the same amount of time (by day 
four) regardless if they were using the NT device. 
     During the treatment run trial, the test subjects had no pain on day five while using the 
NT device compared to the control in which the subjects still had some pain on day five. 
The males had significant pain through day two on the control run compared to 
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significant pain only through day one on the treatment run when using the NT device. 
The female pain ratings indicated significantly elevated pain ratings from baseline in the 
treatment trial until day three compared to the control trial where pain ratings were only 
significantly elevated from baseline until day two, indicating that the females had higher 
amounts of pain while using the NT device. 
     In conclusion, the results indicated statistically there was no significant difference in 
CRP or pain levels between the control run and treatment run therefore, my hypothesis 
was rejected. However upon closer inspection, the data suggests the test subjects 
recovered one day earlier when using the NT device compared to the control. Statistically 
this may not be significant, but a full day recovery for a professional athlete is very 
important. Gender differences were found in response to the control and treatment run. It 
appears based on the present study that males respond better to being treated with NT 
compared to the females in reducing inflammation following a 20 mile run.   
Application 
     There are many devices used to help athletes recover faster. Unfortunately, many of 
them do not work as advertised, and many have not undergone sufficient scientific 
research to support or reject their claims. Coaches, athletic trainers, and athletes should 
seek scientific support of therapeutic interventions which claim to help reduce the effects 
of muscle damage, DOMS, and speed of recovery from exercise and athletic endeavors.  
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Limitations  
Limitations of the study were identified as follows:  
1. Running weather conditions varied. Warmer and cooler temperatures can 
influence cardiac drift and level of hydration which can affect heart rate, exercise 
performance, and DOMS (thereby affecting the release of biochemical markers of 
muscle damage). 
2. The sample was one of convenience and was small (N=10), requiring caution 
when making extrapolations from the results to larger populations. 
3. Variables which could affect enzyme activity such as training level, muscle fiber 
composition, past injuries, and the degree of hormonal activity, were not 
controlled. 
4. In the study performed by Cantanese (30), sensitivity of CRP was to 1 mg/L. We 
outsourced the measurement of CRP to a local hospital where CRP was only 
sensitive to 2.9 mg/L. Clinically, any measurement of CRP of 2.9 mg/L or less is 
acceptable. However, lower CRP values could have a significant impact on the 
outcome of the study.  
Future Research Recommendations 
1. Future research is needed with a larger sample size.  
2. Future research examining a different population such as sedentary, untrained, or 
elderly populations is needed to determine if the NT device would function better 
with untrained individuals. 
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3. Future research including other markers of muscle damage and inflammation such 
as CK, LDH, and Mb is needed to obtain a clearer picture of the mechanism and 
to determine if there is a relationship between the biochemical markers. 
4. Future research is needed that focuses on other types of exercise, besides long 
distance running, which may also cause muscle damage.  
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FUNCTIONAL SCHEMATIC OF NORMATEC RECOVERY DEVICE 
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AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire 
                                          Assess your health needs by marking all true statements. 
              History  
           You have had:  
               ___ A heart attack      
               ___ Heart surgery  
               ___ Cardiac catheterization  
               ___ Coronary angioplasty (PTCA)  
               ___ Pacemaker/implantable cardiac defibrillator/rhythm disturbance  
               ___ Heart valve disease 
               ___Heart Failure 
              ___ Heart transplantation                                                                                  
              ___ Congenital heart disease 
         Symptoms  
              ___ You experience chest discomfort with exertion.  
              ___ You experience unreasonable breathlessness.  
              ___ You experience dizziness, fainting, blackouts.  
              ___ You take heart medications.  
          Other health issues  
               ___ You have diabetes  
               ___ You have or asthma other lung disease.  
               ___ You have burning or cramping in your lower legs  
                      when walking short distances.  
               ___ You have musculoskeletal problems that limit your physical activity 
   —– You have concerns about the safety of exercise. 
               —-- You take prescription medication(s) 
               —-- You are pregnant 
__________________________________________________________________________________________________________ 
        Cardiovascular risk factors  
              ___ You are a man older than 45 years.  
              ___ You are a woman older than 55 years, you  
               have had a hysterectomy, or you are postmenopausal.  
              ___ You smoke, or quite within the previous 6 mo.  
              ___ Your blood pressure is greater than 140/90.  
              ___ You don't know your blood pressure.  
              ___ You take blood pressure medication.  
              ___ Your blood cholesterol level is >200 mg/dL.  
              ___ You don't know your cholesterol level.  
              ___ You have a close blood relative who had a heart attack before age 55 (father or brother) or age  
        65 (mother or  sister).  
              ___ You are physically inactive (i.e., you get less than 30 min. of physical activity on at least 3  
                      days per week).  
              ___ You are more than 20 pounds overweight 
______________________________________________________________________________________ 
   ___ None of the above is true.  
 
If you marked any of these statements in this section, we 
require a physician’s release, attached, in order to continue 
with the joining process.   
If you marked two or more of the statements in this section 
you are required to obtain a physician’s release, attached, in 
order to join the facility.   
You should be able to exercise safely without consulting 
your physician or other healthcare provider in a self-guided 
program or almost any facility that meets your exercise 
program needs. 
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INFORMED CONSENT FOR PARTICIPATION 
Effects of Intermittent Pneumatic Compression on Delayed Onset Muscle Soreness 
in Long Distance Runners  
 
Introduction 
You have been asked to participate in a research study to be conducted in the Human 
Performance Laboratory at Cleveland State University. The purpose of this study is to 
measure the recovery process from prolonged distance running with the use of NormaTec 
Recovery system and its effect on reducing delayed onset muscle soreness (DOMS). 
Previous studies have documented the delayed onset of muscle soreness is an effect of 
performing an exercise which places a great deal of strain on the skeletal muscles. The 
subsequent strain that is placed on the muscles leads to the release of biochemical 
markers into the blood. These biochemical markers indicate damage has been done to the 
muscle and can lead to muscle soreness.  One of these biochemical markers is lactate 
dehydrogenase (LDH). Inflammation is the precursor to full recovery of damaged muscle 
fibers. Inflammation is indicated by another blood marker called C- reactive protein 
(CRP). C- reactive protein indicates the healing process is underway. NormaTec is a 
company which has developed a device used by athletes to help them recover faster. It 
utilizes intermittent pneumatic compression  cuffs to inflate, hold, and deflate different 
areas of the leg aiding in blood flow, profusion, and return back to the heart (similar to 
message).  
 
Procedures 
I understand that I will be asked to perform a maximal graded exercise test to establish 
run intensity. I understand a continuous measurement of oxygen consumption will be 
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recorded throughout the test.  Oxygen consumption will be measured using the Cosmed 
K4 b2 portable oxygen analyzer. I understand that this test involves running at 
comfortable training pace with the treadmill elevating 3% every three minutes until I 
reach a maximal grade in which I cannot continue the run. I understand that this test takes 
approximately 10-15 minutes and is dependent on my conditioning.  Values usually range 
for someone of my ability between 45 and 60 milliliters of oxygen per kilogram of body 
weight each minute.   I know that I can voluntarily stop exercise if I experience any 
problems. 
We ask that you do not do any hard training 48 hours prior to the initial testing. After the 
initial testing you will report to the Human Performance laboratory where baseline data 
will be obtained prior to your long run, this involves a venous blood sample, height, and 
weight.  You will then be instructed to complete a 20 mile run at approximately 70 % of 
your maximal heart rate (moderate intensity). Blood samples will be drawn immediately 
after the run and each day after until baseline measures are again achieved. 
You will complete the same run twice. After one of the runs you will be treated with 
NormaTec recovery system (60 minute duration) daily until blood markers return to 
normal. The second run will be the control where only the blood markers will be 
measured and no NormaTec treatment will be given. During the days after your long run 
we ask that you refrain from training while recovery is being evaluated. 
 
Risks and Discomforts 
I understand that during maximal exercise testing, there exists the possibility of certain 
changes occurring; these include abnormal blood pressure, fainting, disorders of the heart 
rhythm, and rare instances of heart attack, stroke or death (1:20,000 exercise tests).   I 
understand the laboratory has emergency procedures in place and every effort will be 
made to minimize these risks. The laboratory is equipped with an AED and all lab 
personnel are trained in CPR and First Aid.  Emergency procedures including calling 
EMS (x911) stating to the dispatcher:” We have a medical emergency in the Human 
Performance Laboratory PE Building- Room B60”. CPR/First aid will be administered 
until EMS arrives.  Emergency procedures are posted throughout the laboratory. I also 
know that I can voluntarily stop exercise if I experience any problems 
I understand other risks associated with this study include muscle soreness resulting from 
the 20 mile run. Discomfort will also be experienced from giving venous blood samples. 
The risk associated with the run would be the same experienced from your normal 
training regimen. Every effort will be made to minimize these risks. A registered nurse 
will perform all the blood samples drawn and a qualified technician will be responsible 
for administering the NormaTec treatment. 
69 
 
 
Benefits 
The benefits of the study are significant because it will help further our understanding of 
therapeutic interventions to help reduce the effects of muscle damage, DOMS and speed 
of recovery from exercise and athletic endeavors. The results of this study could be 
applied to professional and non-professional athletes who spend a great deal of time 
training, especially those who perform long duration eccentric exercises.  The NormaTec 
treatment system can aid in decreasing recovery time so that training can continue sooner.   
 
Confidentiality  
To protect your privacy, your name will not be used in any document of the project. The 
information, however, may be used for a statistical or scientific purpose with your right of 
privacy retained. 
 
Participation  
I understand that participation in this project is voluntary and that I have the right to 
withdraw at any time with no consequences. I understand that if I have any questions 
about my rights as a participant, I can contact Cleveland State University’s Review Board 
at (216) 687-3630, and if I have any questions about the procedures I can contact Dr. 
Kenneth Sparks at (216) 687-4831 or Mr. Shane Draper at (440) 313-2909.  I also 
understand that I will be compensated ($200) for my time. 
I attest and verify that I have no known health problems that could prevent me from 
successfully participating in the sub-maximal graded exercise test. 
 
Patient Acknowledgement 
The procedure, purposes, known discomforts and risks, possible benefits to me and to 
others have been explained to me. I have read the consent form or it has been read to me, 
and I understand it. 
I agree to participate in this program. I have been given a copy of this consent form. 
Signature: ________________________________________     Date: ____________ 
Witness: __________________________________________    Date: ____________ 
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Cleveland 
State 
University 
     engaged/earning 
 
 
 
 
                                Memorandum 
 
                                                 Institutional Review Board 
 
 
To: 
 
 
 
From: 
Kenneth Sparks 
HPERD, PE 860 
 
Craig M. Zullig 
Director 
Office of Sponsored Programs & Research 
 
Date:  August 26, 2013 
 
 
Re: Results of IRB Review of your project number:  #29876-SPA-HS 
Co-Investigator:  Shane Draper, Student 
Title:   Effects of Intermittent Pneumatic Compression on Delayed Onset Muscle 
Soreness (DOMS) in Long Distance Runners 
 
The IRB has reviewed and approved your application for the above named project, under the 
category noted below.  Approval for use of human subjects in this research is for a one-year period 
as noted below.  If your study extends beyond this approval period, you must contact this office to 
initiate an annual review of this research. 
 
By accepting this decision, you agree to notify the IRB of: (1) any additions to or changes in 
procedures for your study that modify the subjects' risk in any way; and (2) any events that affect that 
safety or well-being of subjects. Notify the IRB of any revisions to the protocol, including the addition 
of researchers,  prior to implementation. 
 
Thank you for your efforts to maintain compliance with the federal regulations for the protection of 
human subjects. 
 
 
 
 
Approval Category: Approval Date: 
 
Expedited (7) Expiration Date: 
August 26, 2013 
 
August 25, 2014
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